A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Mounjaro was launched in India earlier this year, while many leading multinational pharma companies are in the race to ...

A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk in older ...

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

GLP-1 agonists like Ozmepic may provide protection against dementia. A recent study suggests that semaglutide, found in ...

If this is going to become a food trend and we’re making money off of it too, then it’s worth doing,” one restaurateur told The Post.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could ...

Ozempic and Wegovy have been hailed as wonder drugs when it comes to weight loss. But as the drug has become more widely used ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...